July 26 (Reuters) - Immuron Ltd IMC.AX :
* IMMURON US DOD NAVAL MEDICAL RESEARCH CENTER RECEIVES
FEEDBACK
ON IND APPLICATION FOR NEW CAMPYLOBACTER ETEC THERAPEUTIC
* IMMURON LTD - RECEIVED FEEDBACK FROM U.S. FDA AFTER REVIEW
OF
IND FOR A NEW ORAL THERAPEUTIC TARGETING CAMPYLOBACTER AND ETEC
* IMMURON - AGENCY SPECIFIED IND DOES NOT CONTAIN
SUFFICIENT
INFORMATION REQUIRED UNDER 21 CFR 312.23 TO ASSESS RISK TO
SUBJECTS IN PROPOSED STUDIES
* IMMURON - IND PLACED ON CLINICAL HOLD UNTIL FDA HAVE
RECEIVED,
REVIEWED RESPONSE FROM NMRC JUSTIFYING DOSING, SAFETY
MONITORING, RISK MITIGATION PLAN
Source text for Eikon: ID:nGNX9nH9sr
Further company coverage: IMC.AX
((Reuters.Briefs@thomsonreuters.com;))